La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Nektar Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Nektar Therapeutics..

Nektar Therapeutics (NASDAQ:NKTR) Azioni, Catena delle Opzioni

NEKTAR THERAPEUTICS

Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Constellation Brands

Pre-Market Outlook

NKTR

PRGS

Una delle aziende sotto i riflettori potrebbe subire un movimento improvviso, trainata dai prossimi annunci finanziari.

Futures USA: una di queste aziende può volare o crollare. Ecco quale

Biotech

News

General

FDA Grants Nektar Therapeutics Fast Track Designation For Rezpegaldesleukin For Treatment Of Severe-To-Very Severe Alopecia Areata

Deep-pocketed investors have adopted a bullish approach towards Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NKTR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Nektar Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 40% bearish. Among these notable options, 5 are puts, totaling $168,473, and 5 are calls, amounting to $150,313.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $15.0 to $29.0 for Nektar Therapeutics over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Nektar Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Nektar Therapeutics's whale trades within a strike price range from $15.0 to $29.0 in the last 30 days. 
<h3>Nektar Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753300854_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NKTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$3.0</td>
<td>$2.6</td>
<td>$2.6</td>
<td>$21.00</td>
<td>$56.1K</td>
<td>1.0K</td>
<td align="right">597</td>
</tr>
<tr>
<td>NKTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$3.6</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$23.00</td>
<td>$40.3K</td>
<td>777</td>
<td align="right">149</td>
</tr>
<tr>
<td>NKTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$2.75</td>
<td>$2.6</td>
<td>$2.6</td>
<td>$21.00</td>
<td>$31.9K</td>
<td>1.0K</td>
<td align="right">361</td>
</tr>
<tr>
<td>NKTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$4.0</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$25.00</td>
<td>$30.0K</td>
<td>1.2K</td>
<td align="right">201</td>
</tr>
<tr>
<td>NKTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$3.0</td>
<td>$2.25</td>
<td>$2.75</td>
<td>$26.00</td>
<td>$27.5K</td>
<td>78</td>
<td align="right">100</td>
</tr>
</tbody>
</table>

<h3>About Nektar Therapeutics</h3>
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
After a thorough review of the options trading surrounding Nektar Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Nektar Therapeutics</h3>
<ul>
<li>With a trading volume of 768,388, the price of NKTR is up by 1.39%, reaching $24.82.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 15 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Nektar Therapeutics</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $102.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from B. Riley Securities keeps a Buy rating on Nektar Therapeutics with a target price of $85. 
&#x2A; An analyst from HC Wainwright &amp; Co. persists with their Buy rating on Nektar Therapeutics, maintaining a target price of $120. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Nektar Therapeutics with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

Nektar Therapeutics's Options: A Look at What the Big Money is Thinking

B. Riley Securities analyst Mayank Mamtani maintains Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy and raises the price target from $60 to $85.

Price Target

Analyst Ratings

B. Riley Securities Maintains Buy on Nektar Therapeutics, Raises Price Target to $85

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering of $100 million of shares of its common stock. Nektar is selling 4,255,320 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $23.50 per share. The gross proceeds to Nektar from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Nektar has granted the underwriters a 30-day option to purchase up to an additional 638,298 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.&nbsp;All of the securities being sold in this offering are being offered by Nektar. The offering is expected to close on July 2, 2025, subject to the satisfaction of customary conditions.
Nektar intends to use the net proceeds from the offering for general corporate purposes, which may include research and development, clinical development and manufacturing costs to support the advancement of its drug candidates, as well as other general corporate purposes.
 &nbsp;

Offerings

Nektar Therapeutics Prices Underwritten Public Offering Of $100M Of Shares At $23.50/Shr

U.S. futures slipped on Tuesday after two days of record-setting advances. Futures of major benchmark indices were trading lower.
Nasdaq and S&amp;P 500 scaled new highs on Monday. The Donald Trump administration is reportedly lowering its aspirations for comprehensive reciprocal deals. Instead, it is <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46188192/trump-administration-reportedly-scales-back-ambitions-for-comprehensive-trade-deals-before-tariff-deadline">favoring narrower agreement</a>s to avoid the reimposition of U.S. tariffs.
According to a Reuters report, the U.S. will resume trade negotiations with Canada immediately after Ottawa <a href="https://www.benzinga.com/markets/tech/25/06/46161429/canada-rescinds-digital-services-tax-after-trump-calls-it-a-blatant-attack-on-america">rescinded its digital services tax</a> targeting U.S. technology firms.
Meanwhile, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-06-30/eu-to-accept-trump-s-universal-tariff-but-seeks-key-exemptions">reported</a> that the European Union is willing to accept a trade arrangement with the U.S. that includes a 10% universal tariff on many of the bloc's exports. However, it wants the U.S. to commit to lower rates on key sectors such as pharmaceuticals, alcohol, semiconductors, and commercial aircraft. 
The 10-year Treasury bond yielded 4.19% and the two-year bond was at 3.70%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 78.8% likelihood of the Federal Reserve keeping the current interest rates unchanged in its July meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.10%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.23%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.28%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.19%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Tuesday. The SPY was down 0.15% at $616.92, while the QQQ declined 0.19% to $550.60, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro </a>data.
Cues From Last Session:
U.S. stocks settled higher on Monday, with the S&amp;P 500 hitting another record close, as information technology, financial, and real estate sectors recorded the biggest gains. However, energy and consumer discretionary stocks bucked the overall market trend, closing the session lower.
President Trump signaled openness to extending the July 9 deadline for reinstating reciprocal tariffs, adding that he remained optimistic about reaching key agreements in the coming weeks.
On the economic front, the Chicago PMI fell to 40.4 for June from 40.5 in May, and compared to market estimates of 42.7. The Dallas Fed's general business activity index for Texas manufacturing climbed to a reading of -12.7 in June compared to -15.3 in the previous month.
Hewlett-Packard Enterprise Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) and Juniper Networks Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) reached an agreement with the U.S. Department of Justice (DOJ) on Saturday.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.47%</td>
<td>20,369.73</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.52%</td>
<td>6,204.95</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.63%</td>
<td>44,094.77</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.12%</td>
<td>2,175.04</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Despite signals of a cooling economy and what he describes as a &#8220;too tight&#8221; Federal Reserve policy, economist Jeremy Siegel sees a bullish path ahead for equities, predicting major indexes could climb another &#8220;5%-10%&#8221; before any significant reckoning from tariff hits.
&#8220;FOMO could add another 5%-10% to major indexes before earning a reckoning with any tariff earnings hit,&#8221; he said.
Markets, already notching fresh all-time highs, are benefitting from a confluence of factors, including de-escalated geopolitical tensions and a retreat in oil prices, he explains.
Siegel points to falling bond yields, with the 10-year Treasury in the &#8220;4.25%-4.30% range,&#8221; as a clear sign that the Fed&#8217;s stance remains restrictive. While personal income data has cooled and housing is &#8220;feeling the pinch of too-high interest rates,&#8221; Siegel believes these factors provide &#8220;ample cover&#8221; for the Fed to pivot.
However, he doesn&#8217;t expect a rate cut at the July 30 meeting, anticipating 25-basis point cuts at each of the subsequent three meetings into early 2026.
According to Siegel, corporate America is coping, with companies like Nike beating estimates despite a &#8220;tariff hit.&#8221; The prevailing skepticism among traders, evidenced by an elevated VIX, suggests that &#8220;FOMO could add another 5%-10% to major indexes.&#8221;
This momentum, he states, will be driven by &#8220;squeezed shorts, AI productivity and margin improvements,&#8221; emphasizing that &#8220;AI adoption can drive outsized efficiency gains&#8221; even in less direct plays like small-cap value.
Meanwhile, giving her outlook on Gold, Aksha Kamboj, the executive chairperson of Aspect Global Ventures, said, &#8220;Gold prices appear to have stabilized at lower levels and are gradually moving higher, driven by expectations that the U.S. Federal Reserve may implement deeper interest rate cuts in 2025 than previously forecast.&#8221;
&#8220;Key events such as the upcoming July 9 tariff deadline and this week's jobs data are likely to be major market catalysts. Strong demand from central banks and domestic buyers is expected to provide support to the precious metal,&#8221; she added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>June&#8217;s S&amp;P final U.S. manufacturing PMI will be out by 9:45 a.m., and May&#8217;s construction spending and job openings data will be released by 10:00 a.m. ET.</li>
<li>June&#8217;s ISM manufacturing data will be out by 10:00 a.m., whereas auto sales data will also be released on Tuesday.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>MSC Industrial Direct Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) was up 0.80% in premarket on Tuesday as analysts expect it to report quarterly earnings of $1.03 per share on revenue of $970.23 million before the opening bell.</li>
<li>Constellation Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) was 0.037% below the flatline as analysts expect it to report earnings of $3.31 per share on revenue of $2.55 billion, after the closing bell.</li>
<li>Greenbrier Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) was 0.11% higher as analysts expect it to report quarterly earnings of 98 cents per share on revenue of $785.72 million after the closing bell.</li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) tumbled 2.98% after disclosing a proposed public offering of common stock.</li>
<li>Progress Software Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) slipped 3.71% after posting better-than-expected earnings for the second quarter, while sales missed estimates. The company also raised its guidance for FY2025.</li>
<li>AeroVironment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) declined 4.90% after it announced plans to offer $750 million of common stock and $600 million of convertible senior notes in proposed public offerings.</li>
<li>Wolfspeed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) surged over 80% in premarket after implementing a prepackaged restructuring plan supported by most of its lenders. This move aims to cut its debt by ~$4.6 billion or 70% and annual cash interest payments by ~60%, positioning it for accelerated growth and profitability by late third quarter.</li>
<li>Prestige Wealth Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWM#NASDAQ">PWM</a>) zoomed 68.09% after divesting its Prestige Assets International Inc. subsidiary and its three units on June 25, to sharpen its focus on technology-driven wealth management.</li>
<li>Bitmine Immersion Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) gained 21.33% after announcing a $250 million private placement to launch its Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) Treasury Strategy, aiming to become one of the largest publicly traded ETH holders.</li>
<li>Gibo Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>) declined over 7% after testing its AI-driven GIBO Click engine on uDrama, a rapidly growing global short drama platform.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.14% to hover around $65.20 per barrel.
Gold Spot US Dollar rose 1.11% to hover around $3,339.46 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.33% at the 96.5570 level.
Asian markets ended on a mixed note on Tuesday, as Hong Kong's Hang Seng, Japan's Nikkei 225, Australia's ASX 200 indices declined, and India's S&amp;P BSE Sensex, China&#8217;s CSI 300, and South Korea's Kospi indices rose. European markets were lower in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46188237/bill-gates-is-betting-two-thirds-of-his-foundations-portfolio-in-these-3-stocks">Bill Gates Is Betting Two-Thirds Of His Foundation&#8217;s Portfolio In These 3 Stocks</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

$ETH

AVAV

BMNR

GIBO

JNPR

WOLF

US Stock Futures Slip After Two Days Of Record Advances: 'FOMO Could Add Another 5%-10%…,' Says Expert

With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Wall Street expects MSC Industrial Direct Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) to report quarterly earnings at $1.03 per share on revenue of $970.23 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. MSC Industrial Direct shares slipped 0.1% to $84.96 in after-hours trading.</li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) disclosed a proposed public offering of common stock. Nektar Therapeutics fell 2.4% to $25.22 in the after-hours trading session.</li>
<li>Analysts are expecting Constellation Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) to post earnings at $3.31 per share on revenue of $2.55 billion for the latest quarter. The company will release earnings after the markets close. Constellation shares rose 0.5% to $163.49 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>Progress Software Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) posted better-than-expected earnings for the second quarter, while sales missed estimates. The company also raised its guidance for FY2025. Progress Software shares fell 7.2% to $59.27 in the after-hours trading session.</li>
<li>Analysts expect The Greenbrier Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) to post quarterly earnings at 98 cents per share on revenue of $785.72 million after the closing bell. Greenbrier shares gained 1% to $46.50 in after-hours trading.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in">5 Stocks In The Spotlight: Wall Street&#8217;s Most Accurate Analysts Weigh In</a> </li>
</ul>
Photo courtesy: T. Schneider / Shutterstock.com

MSC Industrial Direct, Constellation Brands And 3 Stocks To Watch Heading Into Tuesday

Nektar Therapeutics Announces Proposed Public Offering Of Common Stock, Size Not Disclosed

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) released on Tuesday statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD <a href="https://www.benzinga.com/news/health-care/25/06/46074205/nektar-therapeutics-shares-double-on-promising-eczema-drug-data" target="_blank" rel="noreferrer noopener">study of investigational rezpegaldesleukin</a>.
The trial met its primary endpoint of the <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">mean improvement in Eczema</a> Area and Severity Score (EASI) from baseline at week 16 for all three dose arms of rezpegaldesleukin versus placebo.
All three dose arms also achieved statistical significance at week 16 for the key secondary endpoints of EASI-75 (percent of patients who achieve ≥75% reduction in EASI from baseline), EASI-50 (percent of patients who achieve ≥50% reduction in EASI from baseline) and BSA (mean percent improvement in Body Surface Area score from baseline).
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/46074205/nektar-therapeutics-shares-double-on-promising-eczema-drug-data" target="_blank" rel="noreferrer noopener">Nektar Therapeutics Shares Double On Promising Eczema Drug Data</a>
After 16 weeks, patients had a 53% to 61% improvement in symptoms. This was compared to a 31% improvement for the placebo group.
William Blair writes, &#8220;We believe the efficacy parameters of rezpeg appear to be comparable to the OX40 drug class though numerically lower than Dupixent across the Phase IIb programs.&#8221;
Given the chronic nature of atopic dermatitis, analyst Andy Hsieh wrote that the high frequencies (high 30% to high 40% across a broader set of rezpeg safety data that includes the Phase 2b results) of injection site reactions versus Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)/Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (in the high-single- to mid-double-digit percent range) could be a commercial liability for rezpeg.
If rezpeg indeed demonstrates a remittive effect, it could mitigate injection site reactions, though investors will have to wait until the next update (Phase IIb REZOLVE-AD maintenance data) in early 2026 or 52-week off-treatment results in 2027.
The analyst adds, &#8220;Since we believe there is an absence of clear differentiation in the highly competitive atopic dermatitis field, we view today's stock reaction (up roughly 135%) as a valuation normalization event and not a reflection of investors ascribing value to a differentiated asset. Essentially, Nektar shares now trade around the company's current cash levels. We await further updates to gain appreciation of rezpeg&#8217;s potential remittive effect, which could elevate the asset against competitive offerings.&#8221;
NKTR Price Action: Nektar Therapeutics stock is up 26.83% at $31.01 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46097909/robinhood-ceo-highlights-retail-investor-interest-in-nvidia-tesla-despite-middle-east-tensions-barely-a-blip" target="_blank" rel="noreferrer noopener">Robinhood CEO Highlights Retail Investor Interest In Nvidia, Tesla Despite Middle East Tensions: &#8216;Barely A Blip&#8217;</a></li>
</ul>

Analyst Color

Health Care

Movers

Trading Ideas

REGN

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?

<h3>Gainers</h3>
<ul>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock increased by 66.2% to $0.31 during Wednesday's regular session. The company's market cap stands at $1.1 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares moved upwards by 58.75% to $0.51. The company's market cap stands at $39.7 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 33.07% to $8.26. The company's market cap stands at $3.5 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) stock moved upwards by 33.01% to $1.41. The company's market cap stands at $17.6 million. </li>
<li>Anbio Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNNN#NASDAQ">NNNN</a>) shares moved upwards by 30.93% to $31.53. The company's market cap stands at $1.0 billion. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock increased by 26.86% to $31.02. The market value of their outstanding shares is at $303.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) stock declined by 26.1% to $2.26 during Wednesday's regular session. The market value of their outstanding shares is at $59.6 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock decreased by 25.69% to $10.53. The market value of their outstanding shares is at $93.2 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock fell 25.2% to $0.51. The market value of their outstanding shares is at $20.8 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock decreased by 21.14% to $4.38. The market value of their outstanding shares is at $3.0 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock declined by 17.65% to $2.1. The company's market cap stands at $18.9 million. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) shares declined by 15.93% to $4.91. The market value of their outstanding shares is at $253.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANVS

BBLG

FBRX

GCTK

NNNN

ONMD

PSTV

VYNE

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesday.
Shares of AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) rose sharply during Wednesday's session after the company reported <a href="https://www.benzinga.com/markets/earnings/25/06/46083155/aerovironment-stock-sinks-despite-better-than-expected-q4-report-heres-why">better-than-expected quarterly financial results</a>.
AeroVironment reported quarterly earnings of $1.61 per share, which beat the $1.42 analyst consensus estimate, according to data from Benzinga Pro. Quarterly revenue came in at&nbsp; $275.05 million, beating the Street estimate of $242.69 million.
AeroVironment shares jumped 24% to $239.57 on Wednesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares jumped 34.1% to $32.81. Nektar Therapeutics recently announced data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.</li>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) gained 31.6% to $5.70 after the company achieved a key 2025 milestone by successfully integrating its advanced Cobra separator process into baseline cell production.</li>
<li>Anbio Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNNN#NASDAQ">NNNN</a>) jumped 27.1% to $30.61.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) jumped 19.9% to $6.24. 19.7% to $6.24 after the company announced it is reducing the size of its team.</li>
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) rose 19.1% to $31.77.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) gained 18.1% to $9.60.</li>
<li>BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) rose 16.3% to $5.03 after the company reported better-than-expected first-quarter financial results and raised its FY26 sales guidance.</li>
<li>Yatsen Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YSG#NYSE">YSG</a>) gained 15.1% to $11.12.</li>
<li>Chime Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>) rose 13% to $32.77.</li>
<li>TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) gained 9.8% to $7.26 after Wedbush upgraded the stock from Neutral to Outperform and raised its price target from $6 to $11.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) rose 9.5% to $35.25.</li>
<li>Light &amp; Wonder, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) gained 9.1% to $93.65.</li>
<li>Korea Electric Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEP#NYSE">KEP</a>) rose 8.6% to $13.70.</li>
<li>TTM Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTMI#NASDAQ">TTMI</a>) gained 6% to $40.12.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) jumped 5.5% to $45.18.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

Earnings

BMBL

CHYM

LIMN

SMCI

TIGR

TTMI

AeroVironment Posts Better-Than-Expected Earnings, Joins QuantumScape, Bumble, BlackBerry And Other Big Stocks Moving Higher On Wednesday

<h3>Gainers</h3>
<ul>
<li>Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares increased by 13.6% to $1.46 during Tuesday's after-market session. The company's market cap stands at $11.1 million. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock rose 11.54% to $1.74. The company's market cap stands at $73.0 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) shares rose 9.11% to $1.04. The company's market cap stands at $18.5 million. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares rose 6.62% to $0.74. The company's market cap stands at $32.9 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares rose 6.62% to $1.12. The market value of their outstanding shares is at $5.6 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock increased by 6.29% to $26.0. The company's market cap stands at $118.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares declined by 11.5% to $1.16 during Tuesday's after-market session. The market value of their outstanding shares is at $8.9 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares fell 10.35% to $0.61. The company's market cap stands at $10.3 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares declined by 10.31% to $12.71. The market value of their outstanding shares is at $84.0 million. </li>
<li>InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) stock declined by 8.55% to $2.25. The market value of their outstanding shares is at $77.2 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) shares declined by 8.09% to $1.25. The market value of their outstanding shares is at $19.0 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares decreased by 7.95% to $0.8. The market value of their outstanding shares is at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CASI

CBUS

CTXR

LIXT

NMTC

NSPR

OTRK

XTLB

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock increased by 128.3% to $21.78 during Tuesday's regular session. The market value of their outstanding shares is at $118.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 106.64% to $0.7. The company's market cap stands at $10.3 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares rose 71.71% to $9.41. The market value of their outstanding shares is at $15.7 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock increased by 32.85% to $16.74. The market value of their outstanding shares is at $260.9 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares increased by 29.29% to $0.71. The company's market cap stands at $10.5 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares rose 27.51% to $25.5. The company's market cap stands at $520.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 37.9% to $1.0 during Tuesday's regular session. The market value of their outstanding shares is at $19.4 million. </li>
<li>Ernexa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock decreased by 19.17% to $1.94. The company's market cap stands at $17.6 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares fell 18.49% to $1.34. The market value of their outstanding shares is at $5.3 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares fell 12.09% to $3.94. The market value of their outstanding shares is at $85.2 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock fell 11.72% to $0.44. The company's market cap stands at $8.0 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares fell 11.6% to $0.23. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

AMRN

ERNA

EYEN

INDP

NTHI

SNGX

TRIB

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 1% on Tuesday.
The Dow traded up 1.11% to 43,054.08 while the NASDAQ gained 1.45% to 19,916.04. The S&amp;P 500 also rose, gaining, 1.07% to 6,089.42.
Check This Out: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Information technology shares jumped by 1.6% on Tuesday.
In trading on Tuesday, energy stocks fell by 1.2%.
Top Headline
The U.S. current account deficit increased by 44.3% to $450.2 billion in the first quarter versus a revised deficit of $312 billion in the fourth quarter and compared to market estimates of a $443.3 billion gap.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) shares shot up 67% to $18.18 after the company announced a $500 million convertible notes private placement for its BNB treasury strategy.</li>
<li>Shares of Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) got a boost, surging 137% to $22.62. The company released statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares were also up, gaining 109% to $0.7135 after the company entered into private placement agreements with accredited investors raising approximately $3.7 million in gross proceeds.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) shares dropped 14% to $6.36 after the company announced a proposed private offering of $250 million in new convertible senior notes.</li>
<li>Shares of Advance Auto Parts, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) were down 9% to $47.23. Goldman Sachs analyst Kate McShane downgraded Advance Auto Parts from Neutral to Sell and lowered the price target from $48 to $46.</li>
<li>Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) was down, falling 31% to $12.82 as the company announced a $1.2 million registered direct offering.</li>
</ul>
Commodities In commodity news, oil traded down 5.7% to $64.60 while gold traded down 2% at $3,326.70.
Silver traded down 1.5% to $35.650 on Tuesday, while copper rose 0.2% to $4.8585.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.11%, while Spain's IBEX 35 Index surged 1.41%. London's FTSE 100 gained 0.01%, Germany's DAX 40 gained 1.60% and France's CAC 40 rose 1.04% during the session.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei gaining 1.14%, Hong Kong's Hang Seng Index gaining 2.06%, China's Shanghai Composite rising 1.15% and India's BSE Sensex rising 0.19%.
Economics
<ul class="wp-block-list">
<li>The U.S. current account deficit increased by 44.3% to $450.2 billion in the first quarter versus a revised deficit of $312 billion in the fourth quarter and compared to market estimates of a $443.3 billion gap.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 3.4% year-over-year in April following a 4.1% gain in the previous month.</li>
<li>The FHFA house price index fell by 0.4% from the previous month in April.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

Eurozone

Commodities

Intraday Update

ARRY

HUSA

Crude Oil Falls Sharply; US Current Account Deficit Widens In Q1

HC Wainwright &amp; Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy and raises the price target from $6.5 to $120.

HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $120

WIIM

Nektar Therapeutics shares are trading higher after the company announced data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 1% on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.62% to 42,846.32 while the NASDAQ gained 1.03% to 19,832.45. The S&amp;P 500 also rose, gaining, 0.68% to 6,066.06.
Check This Out: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Information technology shares jumped by 1.2% on Tuesday.
In trading on Tuesday, energy stocks fell by 1.4%.
Top Headline
TD Synnex Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) reported better-than-expected earnings for the second quarter on Tuesday.
The company posted quarterly earnings of $2.99 per share which beat the analyst consensus estimate of $2.72 per share. The company reported quarterly sales of $14.95 billion which beat the analyst consensus estimate of $14.32 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) shares shot up 155% to $27.83 after the company announced a $500 million convertible notes private placement for its BNB treasury strategy.</li>
<li>Shares of Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) got a boost, surging 95% to $18.65. The company released statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares were also up, gaining 81% to $0.6162 after the company entered into private placement agreements with accredited investors raising approximately $3.7 million in gross proceeds.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) shares dropped 59% to $4.0750.</li>
<li>Shares of Maase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAAS#NASDAQ">MAAS</a>) were down 47% to $5.22.</li>
<li>Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) was down, falling 37% to $11.65 as the company announced a $1.2 million registered direct offering.</li>
</ul>
Commodities In commodity news, oil traded down 4% to $65.82 while gold traded down 2.2% at $3,320.70.
Silver traded down 1.5% to $35.630 on Tuesday, while copper rose 0.9% to $4.8940.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.2%, while Spain's IBEX 35 Index surged 1.6%. London's FTSE 100 gained 0.4%, Germany's DAX 40 gained 1.8% and France's CAC 40 rose 1.3% during the session.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei gaining 1.14%, Hong Kong's Hang Seng Index gaining 2.06%, China's Shanghai Composite rising 1.15% and India's BSE Sensex rising 0.19%.
Economics
<ul class="wp-block-list">
<li>The U.S. current account deficit increased by 44.3% to $450.2 billion in the first quarter versus a revised deficit of $312 billion in the fourth quarter and compared to market estimates of a $443.3 billion gap.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 3.4% year-over-year in April following a 4.1% gain in the previous month.</li>
<li>The FHFA house price index fell by 0.4% from the previous month in April.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

Highest Performances Holdings Inc. - American Depository Shares

MAAS

UPXI

Nasdaq Surges 1%; TD Synnex Posts Upbeat Earnings

Nektar Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock is surging on Tuesday, with a session volume of 4.7 million compared to an average volume 239.7K as per data <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">from Benzinga Pro</a>.
The company released statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46070929/rezolve-ad-phase-2b-study-of-rezpegaldesleukin-meets-primary-and-key-secondary-endpoints-in-patien" rel="noreferrer noopener">investigational rezpegaldesleukin</a>.
The global Phase 2b study is being conducted in 393 patients with moderate-to-severe <a href="https://www.benzinga.com/general/health-care">atopic dermatitis</a>. Patients in the study received three under-the-skin shots of rezpegaldesleukin.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupix" target="_blank" rel="noreferrer noopener">Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron&#8217;s Blockbuster Dupixent In Early Biomarker Response</a>
The trial met its primary endpoint of the mean improvement in Eczema Area and Severity Score (EASI) from baseline at week 16 for all three dose arms of rezpegaldesleukin versus placebo.
All three dose arms also achieved statistical significance at week 16 for the key secondary endpoints of EASI-75 (percent of patients who achieve ≥75% reduction in EASI from baseline), EASI-50 (percent of patients who achieve ≥50% reduction in EASI from baseline) and BSA (mean percent improvement in Body Surface Area score from baseline).
After 16 weeks, patients had a 53% to 61% improvement in symptoms. This was compared to a 31% improvement for the placebo group.
The q2w arms of rezpegaldesleukin (high and middle doses) achieved statistical significance at week 16 for the key secondary endpoints of vIGA-AD 0/1 (percent of patients achieving a score of 0 or 1 on the validated Investigator&#8217;s Global Assessment for Atopic Dermatitis with ≥ 2-point reduction&nbsp;from baseline) and Itch NRS (percent of patients with baseline ≥ 4 who experienced a ≥&nbsp;4-point reduction&nbsp;in the Itch Numerical Rating Score from baseline).
In addition, at week 16, the high dose of 24 µg/kg q2w achieved statistical significance on EASI-90 (percent of patients who achieve ≥ 90% reduction in EASI from baseline).
Across all three dose arms, translational blood biomarker data demonstrate robust on-target and dose-dependent pharmacological activity.
The safety profile for the 16-week induction period for rezpegaldesleukin was consistent with previously reported results.
In the pooled rezpegaldesleukin arms, TEAEs, excluding ISRs, were reported in 60.3% of patients and in 57.5% of placebo-treated patients.
There was no increased risk of conjunctivitis, oral ulcers, or infections, including oral herpes, in the rezpegaldesleukin arms.
Nektar plans to submit these REZOLVE-AD 16-week induction results for presentation at a medical conference later in 2025.
Price Action: NKTR stock is trading higher by 108.6% to $19.90 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46071029/mark-zuckerbergs-ai-dreams-hit-whatsapp-speed-bump-as-openai-perplexity-challenge-meta-on-its-own-turf-report" target="_blank" rel="noreferrer noopener">Mark Zuckerberg&#8217;s AI Dreams Hit WhatsApp Speed Bump As OpenAI, Perplexity Challenge Meta On Its Own Turf: Report</a></li>
</ul>
Photo via Shutterstock

Nektar Therapeutics Shares Double On Promising Eczema Drug Data

<h3>Gainers</h3>
<ul>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock rose 172.2% to $25.97 during Tuesday's pre-market session. The company's market cap stands at $118.3 million. </li>
<li>InMed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) stock moved upwards by 88.53% to $4.62. The company's market cap stands at $2.9 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock increased by 53.21% to $0.84. The market value of their outstanding shares is at $10.5 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 47.43% to $1.05. The market value of their outstanding shares is at $11.5 million. </li>
<li>Crescent Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) stock rose 37.18% to $20.99. The market value of their outstanding shares is at $298.3 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares increased by 24.68% to $0.23. The company's market cap stands at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares decreased by 30.4% to $1.12 during Tuesday's pre-market session. The company's market cap stands at $19.4 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares fell 19.35% to $0.4. The market value of their outstanding shares is at $8.0 million. </li>
<li>ViewBix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIX#NASDAQ">VBIX</a>) shares declined by 14.48% to $3.31. The company's market cap stands at $25.6 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares declined by 13.34% to $1.43. The market value of their outstanding shares is at $5.3 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) stock fell 11.39% to $1.09. The company's market cap stands at $19.0 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock declined by 11.05% to $0.21. The market value of their outstanding shares is at $11.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBIO

DHAI

IBIO

VBIX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

Nektar's Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Phase 2b REZOLVE-AD Trial For Atopic Dermatitis, Showing Efficacy And Safety

Press Releases

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

Nektar Therapeutics Reports First Quarter 2025 Financial Results

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics Announces Proposed Public Offering

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

Comments

Nektar Therapeutics

Nektar Therapeutics (NKTR) Opzioni

Nektar Therapeutics (NASDAQ:NKTR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO